cixutumumab

Cixutumumab is a fully human IgG1 monoclonal antibody that specifically targets the type 1 insulin-like growth factor receptor (IGF-1R). By binding to IGF-1R with high affinity, it blocks the interaction between IGF-1R and its ligands (IGF-I and IGF-II), leading to internalization and degradation of the receptor. This results in inhibition of downstream signaling pathways such as PI3K/AKT, which are involved in cell proliferation and survival. Cixutumumab has demonstrated antineoplastic activity by inducing apoptosis and inhibiting tumor cell growth in preclinical models. It was developed for various solid tumors, including lung cancer, prostate cancer, liver cancer, breast cancer, colorectal cancer, head and neck cancers, neuroendocrine tumors, sarcomas, pancreatic cancer, rhabdomyosarcoma, soft tissue sarcoma, malignant thymoma, esophageal cancer. The drug was originally developed by ImClone Systems using phage display technology from Dyax; ImClone was later acquired by Eli Lilly.

Other names

Anti-IGF-1R Recombinant Monoclonal Antibody IMC-A12Anti-IGF1R Recombinant Monoclonal Antibody IMC-A12Anti-IGF 1R Recombinant Monoclonal Antibody IMC-A12Anti-IGF-1R antibody A12Anti-IGF1R antibody A12Anti-IGF 1R antibody A12